The very first evidence for the IGF/IGF-IR-independent actions of IGFBP-3 was the identification of specific cell surface binding between IGFBP-3 and cell surface proteins and subsequent cell growth inhibition in Hs578T human triple negative breast cancer (TNBC) cells [33,70]. Here, IGFBP3 is linked to triple-negative breast carcinoma.